Vilaprisan

Drug Profile

Vilaprisan

Alternative Names: BAY 1002670; S-PRAnt; S-PRM; sPRM

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Small molecules; Sulfones
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometriosis; Uterine leiomyoma

Most Recent Events

  • 01 Nov 2016 Bayer initiates a phase I pharmacokinetics trial in Healthy volunteers Germany (PO) (NCT02975440)
  • 01 Oct 2016 Bayer HealthCare Pharmaceuticals completes the phase II ASTEROID 2 trial for Uterine leiomyoma in Austria, Belgium, Bulgaria, Czech Republic, Finland, Germany, Hungary, Italy, Lithuania, Norway, Netherlands, Poland, Portugal, Sweden, Spain and United Kingdom (NCT02465814)
  • 31 May 2016 Bayer completes the phase II ASTEROID 1 trial for Uterine leiomyoma in USA, Belgium, Bulgaria, Canada, the Czech Republic, Finland, Germany, Hungary, Japan, Norway, Spain, Sweden and Switzerland (NCT02131662)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top